Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PDE4-IN-13 is a phosphodiesterase 4 (PDE4) inhibitor exhibiting anti-inflammatory and antioxidant activities, with an half maximal inhibitory concentration (IC50) value of 1.56 μM. It is used in the research of chronic obstructive pulmonary disease (COPD) [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | PDE4-IN-13 is a phosphodiesterase 4 (PDE4) inhibitor exhibiting anti-inflammatory and antioxidant activities, with an half maximal inhibitory concentration (IC50) value of 1.56 μM. It is used in the research of chronic obstructive pulmonary disease (COPD) [1]. |
Targets&IC50 | PDE4:1.56 μM |
In vitro | PDE4-IN-13 (Compound 6o) effectively reduces the production of TNF-α induced by lipopolysaccharide (LPS) in RAW264.7 macrophages as well as malondialdehyde (MDA) generation induced by Fe2+ in mouse lung homogenates. Additionally, PDE4-IN-13 exhibits excellent capabilities in reducing Fe3+ and chelating Fe2+ [1]. |
In vivo | PDE4-IN-13 (Compound 6o), administered intraperitoneally at doses of 50 mg/kg and 100 mg/kg, significantly prevented the elevation of serum TNF-α levels in mice induced by LPS [1]. |
Molecular Weight | 340.37 |
Formula | C20H20O5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.